Please assess the completion status of the following clinical trial:

Trial Title: Articaine vs Dexmedetomidine Supplemented Articaine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patient with chronic renal failure on hemodialysis scheduled for radiocephalic fistula creation~Exclusion Criteria:~* Allergy to local anesthetics.~* Infection at the site of needle insertion.~* Those having international normalized ratio more than 1.5.~* Coagulopathy.~* Neuromuscular, or severe hepatic or severe pulmonary disease.~* Those having epilepsy.~* Patients who refused to participate.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: ACTIVE_COMPARATOR): Patients received ultrasound guided supraclavicular block with 40 ml of Articaine hydrochloride 2%
- Group AD (Type: EXPERIMENTAL): Patients received ultrasound guided supraclavicular block with 40 ml articaine 2% mixed with dexmedetomidine (1 µg/kg).

Based on this trial design, predict the completion outcome and termination type (if applicable).